News InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904 Continue Reading Previous InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904Next Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors Related Stories News Appalachian Wireless Among First Regional Carriers to Launch RCS for Business with ClearSky News Saviynt Launches EU Identity Security Offering on French S3NS’s Trusted Cloud News Astra Security Connects Autonomous Pentesting to Claude Code and GitHub Copilot Through New MCP Server News G6 Hospitality’s North American Portfolio Grows to Over 1,600 Hotels News DTEX Introduces Precision Tuner for Continuous AI Security Optimization News Splashtop Joins Microsoft Virus Initiative, Strengthening Protection for Microsoft Environments